{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:00:16Z","timestamp":1761156016051},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Poznan University of Medical Sciences","doi-asserted-by":"crossref","award":["502-14-02223359-10334"],"award-info":[{"award-number":["502-14-02223359-10334"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.cyto.2015.09.018","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T02:05:29Z","timestamp":1444788329000},"page":"288-293","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of serum VEGF with clinical response to anti-TNF\u03b1 therapy for Crohn\u2019s disease"],"prefix":"10.1016","volume":"76","author":[{"given":"Piotr","family":"Eder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Korybalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Lykowska-Szuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Krela-Kazmierczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Stawczyk-Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Klimczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Witowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2015.09.018_b0005","first-page":"303","article-title":"Crohn\u2019s disease phenotype, prognosis, and long-term complications: what to expect?","volume":"71","author":"Cosnes","year":"2008","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.cyto.2015.09.018_b0010","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/MIB.0000000000000103","article-title":"Changing age demographics of inflammatory bowel diseases in Ontario, Canada: a population-based cohort study of epidemiology trends","volume":"20","author":"Benchimol","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.cyto.2015.09.018_b0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cyto.2015.09.018_b0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bpg.2014.05.001","article-title":"Treatment algorithms in Crohn\u2019s \u2013 up, down or something else?","volume":"28","author":"Antunes","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"1","key":"10.1016\/j.cyto.2015.09.018_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cyto.2015.09.018_b0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"10.1016\/j.cyto.2015.09.018_b0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease","volume":"97","author":"Esters","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0040","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1756283X09336364","article-title":"Predicting response to anti-TNF agents for the treatment of Crohn\u2019s disease","volume":"2","author":"Siegel","year":"2009","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn\u2019s disease","volume":"5","author":"Jurgens","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cyto.2015.09.018_b0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn\u2019s disease patients predicts nonresponse to infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.cyto.2015.09.018_b0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.v17.i5.578","article-title":"Role of the endothelium in inflammatory bowel diseases","volume":"7","author":"Cromer","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00054725-200606000-00012","article-title":"Role of angiogenesis in inflammatory bowel disease","volume":"12","author":"Koutroubakis","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2015.09.018_b0070","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00054725-200409000-00011","article-title":"Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn\u2019s disease","volume":"10","author":"Di Sabatino","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2015.09.018_b0075","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1053\/j.gastro.2006.03.054","article-title":"Angiogenesis as a novel component of inflammatory bowel disease pathogenesis","volume":"130","author":"Danese","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2015.09.018_b0080","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MIB.0000000000000004","article-title":"The effects of infliximab and adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients","volume":"20","author":"Algaba","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2015.09.018_b0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National cooperative Crohn\u2019s disease study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2015.09.018_b0090","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.cyto.2015.09.018_b0095","first-page":"116","article-title":"Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease","volume":"49","author":"Griga","year":"2002","journal-title":"Hepatogastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.cyto.2015.09.018_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2036.17.s2.17.x","article-title":"Crohn\u2019s disease: monitoring disease activity","volume":"17","author":"Sostegni","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2015.09.018_b0105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","article-title":"Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases","volume":"8","author":"Sandborn","year":"2014","journal-title":"J. Crohns Colitis"},{"issue":"3","key":"10.1016\/j.cyto.2015.09.018_b0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.giec.2014.03.005","article-title":"Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity","volume":"24","author":"Walsh","year":"2014","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"issue":"5","key":"10.1016\/j.cyto.2015.09.018_b0115","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1572-0241.2004.04129.x","article-title":"Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications","volume":"99","author":"Danese","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0120","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00535-004-1423-9","article-title":"Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease","volume":"39","author":"Konno","year":"2004","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1053\/j.gastro.2008.09.064","article-title":"VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis","volume":"136","author":"Scaldaferri","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2015.09.018_b0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.crohns.2013.06.013","article-title":"Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review","volume":"8","author":"Linares","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.cyto.2015.09.018_b0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"Augustin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cyto.2015.09.018_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ibd.20269","article-title":"Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn\u2019s disease patients","volume":"14","author":"Pousa","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cyto.2015.09.018_b0145","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1873-9946(12)60071-3","article-title":"Relationship between levels of angiogenic and lymphangiogenic factors (ALF) and the extension, endoscopic activity, and acute phase reactants (APR) in patients with ulcerative colitis (UC)","volume":"6","author":"Linares","year":"2012","journal-title":"J. Crohn Colitis"},{"key":"10.1016\/j.cyto.2015.09.018_b0150","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1873-9946(12)60072-5","article-title":"Relationship between histological activity of inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors (ALF)","volume":"6","author":"Algaba","year":"2012","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"10.1016\/j.cyto.2015.09.018_b0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.cyto.2015.09.018_b0160","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1111\/j.1572-0241.2008.02176.x","article-title":"Defining the optimal response criteria for the Crohn\u2019s disease activity index for induction studies in patients with mildly to moderately active Crohn\u2019s disease","volume":"103","author":"Thia","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.cyto.2015.09.018_b0165","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn\u2019s disease complicated by strictures: a systematic review","volume":"7","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2015.09.018_b0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000117306","article-title":"Role of biologics and other therapies in stricturing Crohn\u2019s disease: what have we learnt so far?","volume":"1","author":"Sorrentino","year":"2008","journal-title":"Digestion"},{"key":"10.1016\/j.cyto.2015.09.018_b0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CEG.S41413","article-title":"Measuring disease activity in Crohn\u2019s disease: what is currently available to the clinician","volume":"7","author":"D\u2019Inca","year":"2014","journal-title":"Clin. Expert Gastroenterol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615300715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615300715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:53:38Z","timestamp":1589586818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466615300715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1043466615300715"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2015.09.018","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of serum VEGF with clinical response to anti-TNF\u03b1 therapy for Crohn\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2015.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}